FDA RWD/RWE regulatory considerations in draft guidance highlight opportunities and challenges - Laying groundwork for high-quality evidence to support regulatory decisions | Hogan Lovells

This month, FDA released the latest in a series of agency guidance to advance the development and use of real-world data (RWD) and real-world evidence (RWE) in clinical trial designs...

Related Keywords

United States ,Americans ,Robert Califf ,Stephen Hahn ,Hogan Lovells ,Scott Gottlieb , ,Commissioners Stephen Hahn ,Century Cures Act ,Cures Act ,Biological Product Submissions ,World Data ,Assessing Registries ,Support Regulatory Decision Making ,Biological Products ,